Maravai Lifesciences Holdings (MRVI) Net Margin (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) recorded quarterly Net Margin of 9.69% in Q1 2026, up 92.34% quarter-over-quarter from 126.37% in Q4 2025, and up 10313.0% on a YoY basis from N/an in Q1 2025.
Maravai Lifesciences Holdings (MRVI) Net Margin (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Net Margin history runs 7 years deep, the most recent figure standing at 9.69% for Q1 2026.
- In Q1 2026, Net Margin rose 10313.0% year-over-year to 9.69%; the TTM figure through Mar 2026 stood at 90.01% (up 2981.0% YoY), while the FY2025 annual figure was 124.24%, down 2407.0% from the prior year.
- Net Margin was 9.69% for Q1 2026 at Maravai Lifesciences Holdings, up from 126.37% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 64.57% in Q2 2022 to a low of 249.84% in Q3 2024.
- Historically, Net Margin has averaged 51.06% across 5 years, with a median of 26.53% in 2024.
- The sharpest annual moves came in 2024 and 2025: Net Margin tumbled 22726 bps in 2024, then surged 14161 bps in 2025.
- A 5-year view of Net Margin shows it stood at 42.71% in 2022, then slumped by 447 bps to 148.34% in 2023, then soared by 45 bps to 81.45% in 2024, then sank by 55 bps to 126.37% in 2025, then soared by 92 bps to 9.69% in 2026.
- The last three Net Margin figures came in at 9.69% (Q1 2026), 126.37% (Q4 2025), and 108.23% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Maravai Lifesciences Holdings | 747.50 Mn | 739.10 Mn | 33.70 Mn | -9.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.69% |
| Dec 31, 2025 | -126.37% |
| Sep 30, 2025 | -108.23% |
| Jun 30, 2025 | -147.34% |
| Mar 31, 2025 | -112.81% |
| Dec 31, 2024 | -81.45% |
| Sep 30, 2024 | -249.84% |
| Jun 30, 2024 | -26.53% |
| Mar 31, 2024 | -35.34% |
| Dec 31, 2023 | -148.34% |
| Sep 30, 2023 | -22.59% |
| Jun 30, 2023 | -17.33% |
| Mar 31, 2023 | -1.71% |
| Dec 31, 2022 | 42.71% |
| Sep 30, 2022 | 52.10% |
| Jun 30, 2022 | 64.57% |
| Mar 31, 2022 | 60.12% |
| Dec 31, 2021 | 55.64% |
| Sep 30, 2021 | 64.54% |
| Jun 30, 2021 | 61.76% |